ABSTRACT
BACKGROUND: The prevalence of medical illnesses is high among patients with psychiatric disorders. The current study aimed to investigate multi-comorbidity in patients with psychiatric disorders in comparison to the general population. Secondary aims were to investigate factors associated with metabolic syndrome and treatment appropriateness of mental disorders. METHODS: The sample included 54,826 subjects (64.73% females; 34.15% males; 1.11% nonbinary gender) from 40 countries (COMET-G study). The analysis was based on the registration of previous history that could serve as a fair approximation for the lifetime prevalence of various medical conditions. RESULTS: About 24.5% reported a history of somatic and 26.14% of mental disorders. Mental disorders were by far the most prevalent group of medical conditions. Comorbidity of any somatic with any mental disorder was reported by 8.21%. One-third to almost two-thirds of somatic patients were also suffering from a mental disorder depending on the severity and multicomorbidity. Bipolar and psychotic patients and to a lesser extent depressives, manifested an earlier (15-20 years) manifestation of somatic multicomorbidity, severe disability, and probably earlier death. The overwhelming majority of patients with mental disorders were not receiving treatment or were being treated in a way that was not recommended. Antipsychotics and antidepressants were not related to the development of metabolic syndrome. CONCLUSIONS: The finding that one-third to almost two-thirds of somatic patients also suffered from a mental disorder strongly suggests that psychiatry is the field with the most trans-specialty and interdisciplinary value and application points to the importance of teaching psychiatry and mental health in medical schools and also to the need for more technocratically oriented training of psychiatric residents.
Subject(s)
Antipsychotic Agents , Mental Disorders , Metabolic Syndrome , Male , Female , Humans , Metabolic Syndrome/epidemiology , Metabolic Syndrome/drug therapy , Mental Disorders/epidemiology , Mental Disorders/drug therapy , Antipsychotic Agents/therapeutic use , Mental Health , ComorbidityABSTRACT
BACKGROUND: The COVID-19 pandemic has brought significant mental health challenges, particularly for vulnerable populations, including non-binary gender individuals. The COMET international study aimed to investigate specific risk factors for clinical depression or distress during the pandemic, also in these special populations. METHODS: Chi-square tests were used for initial screening to select only those variables which would show an initial significance. Risk Ratios (RR) were calculated, and a Multiple Backward Stepwise Linear Regression Analysis (MBSLRA) was followed with those variables given significant results at screening and with the presence of distress or depression or the lack of both of them. RESULTS: The most important risk factors for depression were female (RR = 1.59-5.49) and non-binary gender (RR = 1.56-7.41), unemployment (RR = 1.41-6.57), not working during lockdowns (RR = 1.43-5.79), bad general health (RR = 2.74-9.98), chronic somatic disorder (RR = 1.22-5.57), history of mental disorders (depression RR = 2.31-9.47; suicide attempt RR = 2.33-9.75; psychosis RR = 2.14-10.08; Bipolar disorder RR = 2.75-12.86), smoking status (RR = 1.15-5.31) and substance use (RR = 1.77-8.01). The risk factors for distress or depression that survived MBSLRA were younger age, being widowed, living alone, bad general health, being a carer, chronic somatic disorder, not working during lockdowns, being single, self-reported history of depression, bipolar disorder, self-harm, suicide attempts and of other mental disorders, smoking, alcohol, and substance use. CONCLUSIONS: Targeted preventive interventions are crucial to safeguard the mental health of vulnerable groups, emphasizing the importance of diverse samples in future research. LIMITATIONS: Online data collection may have resulted in the underrepresentation of certain population groups.
Subject(s)
COVID-19 , Substance-Related Disorders , Humans , Female , Male , COVID-19/epidemiology , Mental Health , Pandemics , Population Groups , Vulnerable Populations , Communicable Disease Control , Substance-Related Disorders/epidemiology , Depression/epidemiologyABSTRACT
The mental health system in Portugal evolved from an institutional-centred system to a community-based system,a process which began in 1998 and has gathered pace since 2006. The approval and implementation of the Portuguese Mental Health Law and the Portuguese NationalMental Health Care Plan has contributed to the implementation of institutions and regulations aimed at decentralized, local and less restrictive models of care. The implementation and evolution process has been steady and gradual, introducing many of the envisioned changes whilst adapting existing mental health institutions and services. The current article describes this transition process, attempting to identify the strengths and weaknessesof the Portuguese Mental Health System from a community-centred perspective.
ABSTRACT
Se realizó un estudio epidemiológico descriptivo con el objetivo de evaluar el comportamiento de la enfermedad periodontal en un grupo de diabéticos pertenecientes al área de salud del Policlínico Docente Chiqui Gómez Lubián de la ciudad de Santa Clara, entre enero de 2005 y enero de 2006. Se estudiaron 150 pacientes con predominio del sexo femenino, y la media de edad fue de 59,12 años. Las variables exploradas fueron: estado periodontal a través del índice periodontal revisado, tipo de diabetes, tiempo de evolución de la enfermedad, tratamiento medicamentoso aplicado, control metabólico y grado de higiene bucal, según el índice de higiene bucal revisado. Los datos se recogieron mediante: revisión de documentos, entrevistas, examen clínico bucal y análisis de laboratorio. El procesamiento estadístico aplicado permitió conocer que la prevalencia (99,30 porciento) y la gravedad de la enfermedad periodontal se relacionaron significativamente con la higiene bucal y el control metabólico de la diabetes(AU)